Cancer-related interventional research must receive endorsement from the relevant Research Group(s), as mandated by the National Cancer Institute. The two-stage Protocol Review Monitoring System (PRMS) has been structured to support the full range of research embodied by the Cancer Consortium.
The first-stage Research Group review is documented in the Research Group Review Summary available at https://redcap.link/rgr. This form is completed by the Research Group(s) during their review of the protocol.
Key Contacts
PRMS@fredhutch.org for additional information or assistance with Research Group reviews
This first-stage review ensures Research Groups prioritize trials for their patient population and reduce the number of studies that are low-accruing due to competing trials.
The Research Groups meet to evaluate their research portfolio and discuss the feasibility and merit of new studies. Consult the Admin contacts in each Research Group for assistance with scheduling reviews.
Submission to the SRC must take place within three months of the Research Group review to ensure timely and relevant reviews.
Additional information can be found in the Research Group Review Job Aid.
The Research Group review is documented in the Research Group Review Summary available at https://redcap.link/rgr.
At the conclusion of the Research Group review, the Group Director or designee completes the form and returns the PDF copy to the investigator or study team. The completed form must be included in the submission for SRC review.
Research Group disapprovals must be reported at https://redcap.link/rgr or emailed to rejectedprotocols@fredhutch.org.
Each study requires one completed review form that indicates a primary group and collaborating groups (as appropriate).
In most cases, the affiliation or membership of an investigator to a Research Group will be obvious (e.g., a breast cancer study will be reviewed by the Breast Oncology Group).
If your study involves multiple Research Groups, consult with the Group Directors of the affiliated groups to decide which one should serve as the primary group.
Research Group Review must occur before submission for SRC review. These reviews are sequential and not concurrent.
A new study submission will not be scheduled for SRC review until the completed Research Group Review Information Summary is submitted. This form is available at https://redcap.link/rgr. Once complete, a PDF copy of the form is attached to the REDCap email notification and must be included in the submission for SRC review.
VIEW THE GROUPS
Breast Oncology
Director: Jennifer Specht, MD
Co-Director: Hannah Linden, MD
Admin: breastresearch@fredhutch.org
Gastrointestinal Oncology
Director: Gabriela Chiorean, MD
Co-Director: William Harris, MD
Admin: khansen3@fredhutch.org
Global Oncology
Director: Edus H. Warren, MD, PhD
Co-Director(s):
Manoj Menon, MD, MPH
Warren Phipps, MD, MPH
Admin: globaloncology@fredhutch.org
GU/Prostate Oncology
Director: Michael Schweizer, MD
Co-Director(s):
Peter Nelson, MD
Evan Yu, MD
Admin: ppanlas2@fredhutch.org
Gynecologic Oncology
Director: Heidi J. Gray, MD
Co-Director(s):
Barbara A. Goff, MD
John B. Liao, MD, PhD
Elizabeth M. Swisher, MD
Hematologic Malignancies
Director: Ajay Gopal, MD, FACP
Director, Myeloid Malignancies:
Mary-Elizabeth Percival, MD
Director, Multiple Myeloma:
Andrew Cowan, MD
Admin:
uwhemeresearchstartup@fredhutch.org
uwhemmalreg@fredhutch.org
Thoracic, Head, and Neck Oncology
Director: Christina Baik, MD, MPH
Co-Director(s):
Keith Eaton, MD, PhD
Cristina Rodriguez, MD
Admin: hnlstartup@fredhutch.org
Pediatric Oncology
Director: Sarah Leary, MD
Co-Director(s):
Colleen Annesley, MD
Marie Bleakley, MD, PhD, MMSC
Admin: pedspc@fredhutch.org
Population Sciences
Hematopoietic Cell Transplantation (CIM)
Director: Geoffrey Hill, MD, FRACP, FRCPA
Co-Director(s):
Elizabeth Krakow, MD, CM, MS
Filippo Milano, MD, PhD
Admin:
crd-directors-office@fredhutch.org
lsaito2@fredhutch.org
Phase 1 Clinical Trials
Director: Michael Schweizer, MD
Admin:
phase1clinicaltrial@fredhutch.org
baskovi2@fredhutch.org